Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Archaea Symbiont of T. cruzi Infection May Explain Heart Failure in Chagas Disease

Full text
Author(s):
Show less -
Higuchi, Maria de Lourdes [1] ; Kawakami, Joyce T. [1] ; Ikegami, Renata N. [1] ; Reis, Marcia M. [1] ; Pereira, Jaqueline de Jesus [1] ; Ianni, Barbara M. [1] ; Buck, Paula [1] ; da Silva Oliveira, Luanda Mara [1] ; Santos, Marilia H. H. [1] ; Hajjar, Ludhmila A. [1] ; Bocchi, Edimar A. [1]
Total Authors: 11
Affiliation:
[1] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Inst Coracao, Sao Paulo - Brazil
Total Affiliations: 1
Document type: Journal article
Source: FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY; v. 8, NOV 21 2018.
Web of Science Citations: 0
Abstract

Background: Archaeal genes present in Trypanosoma cruzi may represent symbionts that would explain development of heart failure in 30% of Chagas disease patients. Extracellular vesicles in peripheral blood, called exosomes (<0.1 mu m) or microvesicles (>0.1 mu m), present in larger numbers in heart failure, were analyzed to determine whether they are derived from archaea in heart failure Chagas disease. Methods: Exosomes and microvesicles in serum supernatant from 3 groups were analyzed: heart failure Chagas disease (N = 26), asymptomatic indeterminate form (N = 21) and healthy non-chagasic control (N = 16). Samples were quantified with transmission electron microscopy, flow cytometer immunolabeled with anti-archaemetzincin-1 antibody (AMZ 1, archaea collagenase) and probe anti-archaeal DNA and zymography to determine AMZ1 (Archaeal metalloproteinase) activity. Results: Indeterminate form patients had higher median numbers of exosomes/case vs. heart failure patients (58.5 vs. 25.5, P < 0.001), higher exosome content of AMZ1 antigens (2.0 vs. 0.0; P < 0.001), and lower archaeal DNA content (0.2 vs. 1.5, P = 0.02). A positive correlation between exosomes and AMZ1 content was seen in indeterminate form (r = 0.5, P < 0.001), but not in heart failure patients (r = 0.002, P = 0.98). Higher free archaeal DNA (63.0 vs. 11.1, P < 0.001) in correlation with exosome numbers (r = 0.66, P = 0.01) was seen in heart failure but not in indeterminate form (r = 0.29, P = 0.10). Flow cytometer showed higher numbers of AMZ1 microvesicles in indeterminate form (64 vs. 36, P = 0.02) and higher archaeal DNA microvesicles in heart failure (8.1 vs. 0.9, P < 0.001). Zymography showed strong% collagenase activity in HF group, mild activity in IF compared to non-chagasic healthy group (121 +/- 14, 106 +/- 13 and 100; P < 0.001). Conclusions: Numerous exosomes, possibly removing and degrading abnormal AMZ1 collagenase, are associated with indeterminate form. Archaeal microvesicles and their exosomes, possibly associated with release of archaeal AMZ1 in heart failure, are future candidates of heart failure biomarkers if confirmed in larger series, and the therapeutic focus in the treatment of Chagas disease. (AU)

FAPESP's process: 09/14484-4 - New prognostic markers in Chagas disease by the use of nanoscopy
Grantee:Maria de Lourdes Higuchi
Support Opportunities: Regular Research Grants